Publications

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. by Biedenbach DJ, Barrett MS, Croco MA, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 45-50

Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 307-311

Timed kill kinetic studies of levofloxacin, ofloxacin, and ciprofloxacin against Moraxella catarrhalis. by Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 135-137

Correlation of aztreonam susceptibility results obtained with the microscan system to reference tests: Reply. by Jones RN and Marshall SA published in Diagn. Microbiol. Infect. Dis. 1997; 29 (2): 119-120

Cefotaxime in the treatment of prophylaxis of surgical infections. by Wittmann DH, Jones RN, Malledant J and Privitera G published in J. Chemother. 1997; 9 (Suppl 2): 19-33

Vancomycin-resistant Enterococcus raffinosus: Molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program. by Wilke WW, Marshall SA, Coffman SL, Pfaller MA, Edmund MB, Wenzel RP and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (1): 43-49

Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci. by Saraiva IH, Jones RN, Erwin M and Sader HS published in Rev. Assoc. Med. Bras. 1997; 43 (3): 217-222

Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: Use of “direct” inoculation from Bactec 9240 blood culture bottles. by Putnam LR, Howard WJ, Pfaller MA, Koontz FP and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (2): 101-104

In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): A novel orally administered streptogramin combination. The Quality Control Study Group. by Putnam SD, Jones RN and Johnson DM published in Diagn. Microbiol. Infect. Dis. 1997; 28 (3): 139-147

Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. by Pfaller MA, Messer S and Jones RN published in Antimicrob. Agents. Chemother. 1997; 41 (2): 233-235

In vitro evaluation of contemporary β-lactam drugs tested against viridans group and β-haemolytic streptococci. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (4): 151-154

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world Wide. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1989; 28 (4): 157-163

Inducible Amp-C β-lactamase producing Gram-negative bacilli from blood stream infections: Frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). by Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1997; 28 (4): 211-219

Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (3): 199-201

Nosocomial streptococcal blood stream infections in the SCOPE Program: Species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. by Pfaller MA, Jones RN, Marshall SA, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 259-263

In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample. by Pfaller MA, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 273-276

Comparative evaluation of Etest for susceptibility testing Neisseria meningitidis with eight antimicrobial agents. An investigation using U.S. Food and Drug Administration regulatory criteria. by Marshall SA, Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (3): 93-97

Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation. by Marco F, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (1): 55-57

Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria. by Marco F, Barrett MS and Jones RN published in J. Antimicrob. Chemother. 1997; 40 (4): 605-607

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. by Klepser ME, Wolfe EJ, Jones RN, Nightingale CH and Pfaller MA published in Antimicrob. Agents Chemother. 1997; 41 (6): 1392-1395

Antimicrobial activity of RU-66647, a new ketolide. by Jones RN and Biedenbach DJ. published in Diagn. Microbiol. Infect. Dis. 1997; 27(1-2): 7-12

Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (1-2): 21-28

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. by Jones RN, Barrett MS and Erwin ME published in Antimicrob. Agents Chemother. 1997; 41 (2): 488-493

A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. by Jones RN, Jacobs MR, Washington JA and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1997; 27 (3): 75-83

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: Analysis of the correlations between in vitro test results and clinical response. by Jones RN and Dudley MN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (1): 5-18

Critical evaluation of the Vitek GNS F6 card results compared to standardized, reference susceptibility test methods. by Jones RN, Marshall SA and Zerva L published in Diagn. Microbiol. Infect. Dis. 1997; 28 (1): 35-40

Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results. by Jones RN, Barrett MS and Deguchi T published in Diagn. Microbiol. Infect. Dis. 1997; 28 (4): 193-200

Ofloxacin otic solution for treatment of otitis externa in children and adults. by Jones RN, Milazzo J and Seidlin M published in Arch. Otolaryngol. Head Neck Surg. 1997; 123 (11): 1193-1200

Antimicrobial interactions (synergy) of teicoplanin with two broad-spectrum drugs (cefotaxime, ofloxacin) tested against Gram-positive isolates from Germany and the United States. by Jones RN, Marshall SA and Grimm H published in Diagn. Microbiol. Infect. Dis. 1997; 29 (2): 87-94

Nosocomial enterococcal blood stream infections in the SCOPE Program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. by Jones RN, Marshall SA, Pfaller MA, Wilke WW, Hollis RJ, Erwin ME, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1997; 29 (2): 95-102

Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric Gram- negative bacilli: Occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. by Jones RN, Pfaller MA, Marshall SA, Hollis RJ and Wilke WW published in Diagn. Microbiol. Infect. Dis. 1997; 29 (3): 187-192

Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group. by Jones RN, Salazar JC, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 265-272

CQ-397 and CQ-414: Antimicrobial activity and spectrum of two fluoroquinolone—cephalosporin, dual-action compounds with carboxamido bonds. by Johnson DM and Jones RN. published in Clin. Microbiol. Infect. 1997; 3 (3): 335-344

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. by Jamjian C, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (2): 454-459

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing. by Jamjian C, Barrett MS and Jones RN published in Diagn, Microbiol, Infect, Dis, 1997; 27 (4): 129-138

Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 Gram-negative bacteria. by Gales AC, Pignatari AC, Jones RN, Baretta M and Sader HS published in Rev. Assoc. Med. Bras. 1997; 43 (2): 137-144

Antimicrobial susceptibility of Klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL) isolated in hospitals in Brazil. by Gales AC, Bolmstrom A, Sampaio J, Jones RN and Sader HS published in Braz. J. Infect. Dis. 1997; 1 (4): 196-203

Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates. by Flynn CM, Kelley CM, Barrett MS and Jones RN published in J. Clin. Microbiol. 1997; 35 (8): 2083-2086

In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin. by Erwin ME, Varnam D and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (2): 93-100

Multicenter laboratory evaluation of the bioMerieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. by Doern GV, Brueggemann AB, Perla R, Daly J, Halkias D, Jones RN and Saubolle MA published in J. Clin. Microbiol. 1997; 35 (8): 2115-2119

A cluster of serious Escherichia coli infections in a neonatal intensive care unit. by Diekema DJ, Barr J, Boyken LD, Buschelman BJ, Jones RN, Pfaller MA and Herwaldt LA published in Infect. Control Hosp. Epidemiol. 1997; 18 (11): 774-776

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. by Cormican MG and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (1): 204-211

Avoparcin, a glycopeptide used in animal foods: Antimicrobial spectrum and potency tested against human isolates from the United States. by Cormican MG, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 241-248

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. by Biedenbach DJ, Schermer IH and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (1-2): 1-5

Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1997; 35 (12): 3198-3202

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. by Ballow CH, Jones RN, Johnson DM, Deinhart JA, and Schentag JJ published in Diagn. Microbiol. Infect. Dis. 1997; 29 (3): 173-186

Proposed MIC quality control guidelines for National Committee for Clinical Laboratory Standards susceptibility tests using seven veterinary antimicrobial agents: ceftiofur, enrofloxacin, florfenicol, penicillin G-novobiocin, pirlimycin, premafloxacin, and spectinomycin. by Marshall SA, Jones RN, Wanger A, Washington JA, Doern GV, Leber AL and Haugen TH published in J. Clin. Microbiol. 1996; 34 (8): 2027-2029

Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U- 100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials. by Worth S, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 87-91

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. by Jones RN published in Am. J. Med. 1996; 100 (6A): 3S-12S

Critical appraisal of Etest for the detection of fluoroquinolone resistance. by Jones RN, Erwin ME and Croco JL published in J. Antimicrob. Chemother. 1996; 38 (1): 21-25